Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Rating) was the recipient of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 154,900 shares, a decrease of 18.6% from the October 15th total of 190,300 shares. Based on an average daily volume of 75,200 shares, the days-to-cover ratio is presently 2.1 days. Currently, 1.5% of the company's shares are sold short.
Bluejay Diagnostics Stock Performance
Bluejay Diagnostics stock traded up $0.03 during trading on Tuesday, hitting $0.73. The company's stock had a trading volume of 52,876 shares, compared to its average volume of 54,507. The stock's fifty day moving average is $0.84 and its 200 day moving average is $1.03. Bluejay Diagnostics has a 1-year low of $0.61 and a 1-year high of $4.47.
Get Bluejay Diagnostics alerts:Institutional Investors Weigh In On Bluejay Diagnostics
A number of large investors have recently modified their holdings of BJDX. Millennium Management LLC acquired a new stake in shares of Bluejay Diagnostics in the second quarter valued at about $27,000. Virtu Financial LLC acquired a new stake in shares of Bluejay Diagnostics in the second quarter valued at about $45,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Bluejay Diagnostics in the second quarter valued at about $54,000. Institutional investors and hedge funds own 1.21% of the company's stock.
Bluejay Diagnostics Company Profile
(Get Rating)Bluejay Diagnostics, Inc, a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components.
Featured Articles
- Get a free copy of the StockNews.com research report on Bluejay Diagnostics (BJDX)
- Don't Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe's?
- Three Penny Stocks Making Big Moves In November
- Agilent Remains In Buy Range Ahead Of Next Week's Q4 Report
- Wayfair Still Has Its Fair Share of Issues
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.